UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | R | S | T | U | V | W | Y
Number of items: 295.

A

Aiello, A; Du, MQ; Peng, HZ; Pezzella, F; Papini, D; Giardini, R; Pilotti, S; ... Isaacson, PG; + view all (1999) Simultaneous phenotypically distinct but clonally identical mucosa-associated lymphoid tissue and follicular lymphoma in a patient with Sjogren's syndrome. Blood , 94 (7) pp. 2247-2251.

Aiello, A; Giardini, R; Tondini, C; Balzarotti, M; Diss, T; Peng, H; Delia, D; (1999) PCR-based clonality analysis: a reliable method for the diagnosis and follow-up monitoring of conservatively treated gastric B-cell MALT lymphomas? Histopathology , 34 (4) pp. 326-330.

Al-Azraqi, A; Angus, B; Gokul, S; Sinha, D; Calvert, AH; Lunec, J; (1999) Bcl-2 expression is a potential prognostic co-factor with P53-mutation status in epithelial ovarian carcinoma. British Journal of Cancer , 80 178-.

Al-Mufti, RAM; Pedley, RB; Marshall, D; Begent, RHJ; Winslet, MCAH; K, EF; (1999) In vitro assessment of lipiodol targeted radiotherapy for primary and metastatic liver cancers. British Journal of Cancer , 79 pp. 1665-1671.

Allford, SL; Harrison, P; Cohen, H; Mackie, IJ; Machin, SJ; (1999) Platelet activation in thrombotic thrombocytopenic purpura. In: THROMB HAEMOSTASIS. (pp. 361 - 361). F K SCHATTAUER VERLAG GMBH

Allford, SL; Harrison, P; Mackie, IJ; Cohen, H; Machin, SJ; (1999) Platelet activation markers in thrombotic thrombocytopenic purpura. Presented at: UNSPECIFIED.

Aramburu-González, JA; Rodríguez-Justo, M; Jiménez-Reyes, J; Santonja, C; (1999) A case of soft tissue mesenchymal chondrosarcoma metastatic to skin, clinically mimicking keratoacanthoma. Am J Dermatopathol , 21 (4) pp. 392-394.

Ardeshna, KM; Addison, IE; Pizzey, AR; Linch, DC; Devereux, S; Khwaja, A; (1999) P38 stress-activated protein kinase activity is required for the lipopolysaccharide-induced maturation of monocyte-derived dendritic cells. BRIT J HAEMATOL , 105 33 - 33.

Ardeshna, KM; Linch, DC; Devereux, S; Khwaja, A; (1999) p38 stress-activated protein kinase and NF-kappa B activity are required for lipopolysaccharide-induced maturation of monocyte-derived dendritic cells. BLOOD , 94 (10) 214A - 214A.

Ardeshna, KM; Pizzey, AR; Thomas, NSB; Linch, DC; Devereux, S; (1999) Proliferative capacity and susceptibility to retroviral transduction of CD34 and monocyte derived dendritic cells. BRIT J HAEMATOL , 105 29 - 29.

Arnold, J; Holmes, Z; Pickering, W; Regan, L; Cohen, H; (1999) Prevalence of anti-beta 2 glycoprotein 1 IgG antibodies in women with recurrent miscarriage. In: THROMB HAEMOSTASIS. (pp. 535 - 536). F K SCHATTAUER VERLAG GMBH

Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, PJ; Endicott, JA; Gibson, AE; ... Schultz, R; + view all (1999) In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors. British Journal of Cancer , 80 110-.

B

Banks, PM; Isaacson, PG; (1999) MALT lymphoma in 1997. Where do we stand? American Journal of Clinical Pathology , 111 (1 supp) S75-S83.

Barnouin, K; Fredersdorf, S; Eddaoudi, A; Mittnacht, S; Pan, LX; Du, MQ; Lu, X; (1999) Antiproliferative function of p27(kip1) is frequently inhibited in highly malignant Burkitt's lymphoma cells. ONCOGENE , 18 (46) 6388 - 6397.

Bateman, A; Murphy, S; Emiliusen, L; Ruchatz, A; Melcher, A; Fielding, A; Cattaneo, R; ... Vile, RG; + view all (1999) Fusogenic membrane glycoproteins - A novel class of cytotoxic genes with immunostimulatory properties. GENE THERAPY , 6 S6-S6.

Batey, MA; Wright, JG; Simmonds, D; Proctor, M; Chapman, F; Fishwick, K; Azzabi, A; ... Boddy, AV; + view all (1999) Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer. British Journal of Cancer , 80 259-.

Bay, JO; Uhrhammer, N; Pernin, D; Presneau, N; Tchirkov, A; Vuillaume, M; Laplace, V; ... Bignon, YJ; + view all (1999) High incidence of cancer in a family segregating a mutation of the ATM gene: Possible role of ATM heterozygosity in cancer. HUM MUTAT , 14 (6) 485 - 492.

Bentzen, SM; Saunders, MI; Dische, S; (1999) Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiotherapy and Oncology , 53 pp. 219-226.

Berkenstadt, H; Rosenthal, T; Segal, E; Peleg, E; Ben-Ari, G; Perel, A; Hackshaw, A; (1999) Elevated plasma atrial natriuretic peptide levels after occlusion of the thoracic aorta. Chest , 115 (1) pp. 130-134.

Bodmer, JG; Marsh, SGE; Albert, ED; Bodmer, WF; Bontrop, RE; Dupont, B; Erlich, HA; ... Terasaki, PI; + view all (1999) Nomenclature for Factors of the HLA System, 1998. HUMAN IMMUNOLOGY , 60 (4) pp. 361-395.

Bodmer, JG; Marsh, SGE; Albert, ED; Bodmer, WF; Bontrop, RE; Dupont, B; Erlich, HA; ... P, I; + view all (1999) Nomenclature for factors of the HLA system, 1998. European Journal of Immunogenetics , 26 pp. 81-116.

Bodmer, JG; Marsh, SGE; Albert, ED; Bodmer, WF; Bontrop, RE; Dupont, B; Erlich, HA; ... P, I; + view all (1999) Nomenclature for factors of the HLA system, 1998. Vox Sanguinis , 77 pp. 164-191.

Bodmer, JG; Marsh, SGE; Albert, ED; Bodmer, WF; Bontrop, RE; Dupont, B; Erlich, HA; ... P, I; + view all (1999) Nomenclature for factors of the HLA system, 1998. Tissue Antigens , 53 pp. 407-446.

Borthwick, NJ; Wickremasinghe, RG; Lewin, J; Fairbanks, L; Bofill, M; (1999) Activation associated necrosis in HIV infection. The Journal of Infectious Diseases , 179 pp. 352-360.

Borthwick, NJ; Wickremasinghe, RG; Lewin, J; Fairbanks, LD; Bofill, M; (1999) Activation-associated necrosis in human immunodeficiency virus infection. J INFECT DIS , 179 (2) 352 - 360.

Boshoff, C; Weiss, RA; (1999) HHV8/KSHV - Introduction. SEMIN CANCER BIOL , 9 (3) 149 - 150.

Boxer, G; Stuart-Smith, S; Flynn, A; Green, A; Begent, R; (1999) Radioimmunoluminography: a tool for relating tissue antigen concentration to clinical outcome. BRITISH JOURNAL OF CANCER , 80 (5-6) pp. 922-926. 10.1038/sj.bjc.6690443.

Brock, CS; Davies, C; Ledermann, JA; Stein, RC; (1999) A pilot study of infusional chemotherapy FMM (5-fluorouracil, mitoxantrone, methotrexate) in advanced breast cancer. British Journal of Cancer , 80 p. 298.

Brock, CS; Davies, C; Ledermann, JA; Stein, RC; (1999) A pilot study of infusional chemotherapy FMM (5-fluorouracil, mitoxantrone, methotrexate) in advanced breast cancer. BRIT J CANCER , 80 103 - 103.

Brooks, N; McHugh, PJ; Lee, M; Hartley, JA; (1999) The role of base excision repair in the repair of DNA adducts formed by a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size. ANTI-CANCER DRUG DES , 14 (1) 11 - 18.

Brooks, N; Mchugh, PJ; Lee, M; Hartley, JA; (1999) Repair of DNA damage produced by sequence specific minor groove alkylating agent. PROC AM ASSOC CANCER RES , 40 p. 4118.

Buckley, CD; Pilling, D; Henriquez, NV; Parsonage, G; Threlfall, K; Scheel-Toellner, D; Simmons, DL; ... Salmon, M; + view all (1999) RGD peptides induce apoptosis by direct caspase-3 activation. pp. 534-539.

Burcombe, RJ; Ostler, PJ; Ayoub, AW; Hoskin, PJ; (1999) Staging CT scans in prostate cancer treatment: A retrospective audit. British Journal of Cancer , 80 p. 157.

C

CRT, ; Laskey, RA; Williams, GH; Coleman, N; (1999) Determination of cellular growth abnormality. WO/1999/021014.

CRT, ; Laskey, RA; Williams, GH; Krude, T; Stoeber, K; Mills, AD; (1999) A cell-free replication system and uses thereof. WO99/11776.

Calabrese, CR; Thomas, HD; Batey, MA; Boritzki, T; Zhang, K; White, AW; Curtin, NJ; ... Newell, DR; + view all (1999) Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase. Clinical Cancer Research , 5 543-.

Calvert, AH; Hughes, AN; Calvert, PM; Plummer, RE; Highley, MS; (1999) MTA (LY231514) demonstrates clinical activity against malignant mesothelioma in a phase I combination trial with carboplatin. European Journal of Cancer , 35 1146-.

Calvert, AH; Sessa, C; Hughes, A; Jochim, U; Calvert, P; Ghielmini, M; Renard, J; ... Gallant, G; + view all (1999) Pharmacokinetics (PK) of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies. European Journal of Cancer , 35 1147-.

Calvert, H; (1999) MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions. Semin Oncol , 26 (2 Suppl ) pp. 105-108.

Calvert, PM; Highley, MS; Hughes, AN; Plummer, ER; Azzabi, AST; Verrill, MW; Camboni, MG; ... Calvert, AH; + view all (1999) A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors. Clinical Cancer Research , 5 333-.

Campbell, PJ; Tirvengadum, MA; Pickering, W; Cohen, H; Ryan, KE; (1999) HEPTEST: a suitable method for monitoring heparin during pregnancy. Clin Lab Haematol , 21 (3) pp. 193-199.

Cardigan, RA; Crook, M; Mackie, IJ; Machin, SJ; (1999) Increased levels of activated factor XII (FXIIa) in hyperlipidaemia. THROMB HAEMOSTASIS 729 - 729.

Cardigan, RA; McGloin, H; Mackie, IJ; Machin, SJ; Singer, M; (1999) Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney International , 55 (4) pp. 1568-1574.

Cardigan, RA; McGloin, H; Mackie, IJ; Machin, SJ; Singer, M; (1999) Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. KIDNEY INT , 55 (4) 1568 - 1574.

Casey, JL; Pedley, RB; King, DJ; Boden, R; Chapman, AP; Yarranton, GT; Begent, RHJ; (1999) Improved tumour targeting of di-Fab ' fragments modified with polyethylene glycol. TUMOR TARGET , 4 (4) 235 - 244.

Casey, JL; Pedley, RB; King, DJ; Boden, R; Chapman, AP; Yarranton, GT; Begent, RHJ; (1999) Improved tumour targeting of di-Fab' fragments modified with polyethylene glycol. Tumor Targeting , 4 (4) pp. 235-244.

Casey, JL; Pedley, RB; King, DJ; Green, AJ; Yarranton, GT; Begent, RHJ; (1999) Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments. BRIT J CANCER , 81 (6) 972 - 980.

Cassoni, AM; Whelan, JS; (1999) Ewing's sarcoma: hyperfractionated radiotherapy with concurrent chemotherapy: acute toxicity. A prospective single institutional study. In: (pp. p. 45).

Chan, JK; Miller, KD; Munson, P; Isaacson, PG; (1999) Immunostaining for cyclin D1 and the diagnosis of mantle cell lymphoma: is there a reliable method? Histopathology , 34 (3) pp. 266-270.

Chang, J; Powles, TJ; Allred, DC; Ashey, SE; Clark, GM; Makris, A; Assersohn, L; ... Dowsett, M; + view all (1999) Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. Journal Of Clinical Oncology , 17 pp. 3058-3063.

Chester, KA; Melton, RG; Hawkins, RR; (1999) Phage technology for producing antibody enzyme fusion proteins. In: Melton, RG and Fox, RJ, (eds.) Enzyme-Prodrug Strategies for Cancer Therapy. Klewer Academic/Plenum Press

Chitolie, A; Mackie, IJ; Lawrie, AS; Donohue, S; Cohen, H; Machin, SJ; (1999) Evidence of ongoing thrombin generation in patients with prothrombin G -> A 20210 mutation. THROMB HAEMOSTASIS 551 - 552.

Cooke, SP; Pedley, RB; Boden, R; Holliger, P; Winter, G; Begent, RHJ; Chester, KA; (1999) Tumour targeting using MFE-23 :: TNF alpha fusion protein. BRIT J CANCER , 80 85 - 85.

Cooke, SP; Pedley, RB; Boden, R; Holliger, P; Winter, G; Begent, RHJ; Chester, KA; (1999) Tumour targeting using MFE-23::TNF alpha fusion protein. British Journal of Cancer , 80 p. 228.

Cooke, SP; Pedley, RBB; R, H; P, W; G, B; R H J and Chester, KA; (1999) Tumour targeting using MFE::TNF fusion protein. In: (Proceedings) Proceedings BACR, Br J Cancer. (pp. 85-).

Cooooke, SP; Pedley, RB; Boden, R; Holliger, P; Winter, G; Begent, RHJ; Chester, KA; (1999) Tumour targeting using MFE-23::TNF alpha fusion protein. In: (Proceedings) British Journal of Cancer. (pp. p. 228).

Corell, A; Pay, AL; Arguello, JR; Borton, M; Dunne, C; Madrigal, JA; Marsh, SGE; (1999) RSCA (reference strand mediated conformation analysis) resolves HLA-DRB1*04 typing ambiguities where other molecular techniques fail. BLOOD , 94 (10) 318B-318B.

Cox, ST; Marsh, SGE; Scott, I; Clayton, J; Arguello, JR; McWhinnie, AJ; Prokupek, B; ... Little, AM; + view all (1999) HLA-A, -B, -C polymorphism in a UK Ashkenazi Jewish potential bone marrow donor population. TISSUE ANTIGENS , 53 (1) pp. 41-50. 10.1034/j.1399-0039.1999.530105.x.

Cullen, M; Hancock, BW; Gregory, WM; Hudson, GV; Burton, A; Selby, P; Maclennan, KA; ... Linch, DC; + view all (1999) Ch1VPP/PABIOE is superior to PABIOE: Interim results of the British national lymphoma investigation/central lymphoma group randomised trial in advanced Hodgkin's disease. BRIT J CANCER , 80 18 - 18.

Cummins, D; Hoskin, P; Young, J; Goodman, IL; Coupe, MO; Halil, O; Foy, CJ; (1999) Is a man's facial appearance predictive of how he will die? International Journal of Clinical Practice , 53 pp. 140-141.

Curtin, NJ; Kyle, S; Wang, LZ; Durkacz, BW; White, AJ; Srinivasan, S; Griffin, RJ; ... Hostomsky, Z; + view all (1999) Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors. Clinical Cancer Research , 5 520-.

D

De Silva, IU; Clingen, PH; McHugh, PJ; Tilby, MJ; Gregson, SJ; Howard, P; Thurston, DE; (1999) The role of nucleotide excision repair in the repair of DNA damage induced by mono- and bifunctional, major and minor groove alkylating agents. BRIT J CANCER , 80 42 - 42.

DeSilva, IU; Clingen, PH; Mchugh, PJ; Tilby, MJ; Gregson, SJ; Howard, P; Thurston, DE; (1999) The role of nucleotide excision repair in the repair of DNA damage induced by mono- and bifunctional, major and minor groove alkylating agents. British Journal of Cancer , 80 p. 55.

Deighton, A; Winfield, EA; Venables, K; Aird, EGA; Hoskin, PJ; (1999) Variation in dose distribution for breast radiotherapy: A trial based quality assurance programme in the UK. European Journal of Cancer , 35 p. 342.

Delaney, CA; Wang, LZ; Kyle, LZ; Srinivasan, S; White, AW; Curtin, NJ; Calvert, AH; ... Newell, DR; + view all (1999) Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines. British Journal of Cancer , 80 62-.

Delassus, S; Titley, I; Enver, T; (1999) Functional and molecular analysis of hematopoietic progenitors derived from the aorta-gonad-mesonephros region of the mouse embryo. BLOOD , 94 (5) pp. 1495-1503.

Delecluse, HJ; Hummel, M; Marafioti, T; Anagnostopoulos, I; Stein, H; (1999) Common and HIV-related diffuse large B-cell lymphomas differ in their immunoglobulin gene mutation pattern. JOURNAL OF PATHOLOGY , 188 (2) pp. 133-138.

Devereux, S; Corney, C; Macdonald, C; Watts, M; Ward, M; Bank, A; Linch, DC; (1999) Multi-drug resistance (MDR-1) gene transfer in patients with poor prognosis lymphoma undergoing high dose therapy and CD34 selected peripheral blood stem cell transplantation (PBSCT). BONE MARROW TRANSPL , 23 S85 - S85.

Dische, S; Saunders, MI; (1999) The CHART regimen and morbidity [Full text available, price (Pounds)16.45]. Acta Oncologica , 38 pp. 147-152.

Dische, S; Saunders, MI; Sealy, R; Werner, ID; Verma, N; Foy, C; Bentzen, SM; (1999) Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy: a report of a randomised controlled trial. Radiotherapy and Oncology , 53 pp. 93-98.

Diss, TC; Du, MQ; Peng, HZ; Parkinson, MC; Kerr, J; (1999) Parovirus B19 is associated with benign testicular tissue as well as testicular germ cell tumours. Molecular Pathology , 52 (6) pp. 349-352.

Donohoe, S; Kingdom, J; Mackie, I; Jauniaux, E; Machin, S; (1999) beta(2)GPI and Annexin V in normal and APS villous placenta. BRIT J HAEMATOL , 105 28 - 28.

Donohoe, S; Kingdom, JCP; Mackie, IJ; (1999) Affinity purified human antiphospholipid antibodies bind normal term placenta. LUPUS , 8 (7) 525 - 531.

Donohoe, S; Mackie, I; Kingdom, J; Jauniaux, E; Machin, S; (1999) Placental expression of beta(2)GPI and annexin V in normal and APS pregnancies. THROMB HAEMOSTASIS 66 - 66.

Dowsett, M; Smith, IE; Powles, TJ; Salter, J; Ellis, PM; Johnston, SRD; Makris, A; ... Assersohn, L; + view all (1999) Biological studies in primary medical therapy of breast cancer: The Royal Marsden Hospital experience. In: Howell, A and Dowsett, M, (eds.) ESO Scientific Updates. (pp. 113-125). Elsevier Science

Du, MQ; Isaacson, PG; (1999) Genesis and progression of gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Molecular Biology of Haematopoesis , 6 pp. 203-212.

E

Eardley, K; Majumdar, A; Ferrreira, MAS; Howie, AJ; Richards, NT; Savage, COS; Wheeler, DC; ... Lipkin, GW; + view all (1999) Microalbuminuria as a predictor of glomerular disease and renal prognosis in patients with microscopic haematuria. KIDNEY INT , 55 (6) 2586 - 2586.

Enver, T; (1999) B-cell commitment: Pax5 is the deciding factor. CURRENT BIOLOGY , 9 (24) R933-R935. 10.1016/S0960-9822(00)80108-6.

F

Falzetti, D; Vermeesch, JR; Hood, TL; Nacheva, EP; Matteucci, C; Martelli, MF; Van den Berghe, H; ... Mecucci, C; + view all (1999) Identification of multiple copies of a 20q-chromosome in a case of myelodysplastic syndrome: a FISH study. LEUKEMIA RES , 23 (4) 407 - 413.

Fielding, A; Bateman, A; Vile, R; Cosset, FL; Russell, S; (1999) Targeting the cytotoxicity of a fusogenic gibbon ape leukaemia virus envelope glycoprotein by ligand display. GENE THERAPY , 6 S8-S8.

Flynn, AA; Green, AJ; Boxer, G; Pedley, RB; Begent, RH; (1999) A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology. Phys Med Biol , 44 (7) N151-N159.

Flynn, AA; Green, AJ; Boxer, G; Pedley, RB; Begent, RHJ; (1999) A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology. PHYS MED BIOL , 44 (7) N151 - N159.

Flynn, AA; Green, AJ; Boxer, GM; Casey, JL; Pedley, RB; Begent, RHJ; (1999) A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model. INT J RADIAT ONCOL , 43 (1) 183 - 189.

Forster, M; Pande, K; de Takats, D; McCloskey, EV; de Vernijoul, MC; Taboulet, J; Frenkian, M; ... Kanis, JA; + view all (1999) Calcitonin gene receptor polymorphism is not associated with fracture risk factors in a random population sample. In: (pp. S231-S231). AMER SOC BONE & MINERAL RES

Frohlich, B; Paulussen, M; Craft, A; Judson, I; Ladenstein, R; Oberlin, O; Whelan, JS; ... Jurgens, HFEICESS92UE-E99; + view all (1999) Therapiekonzepte bei non-responden/rezidivpatienten mit Eing Sarkomen im kindesalter. In:

G

GUPTA, R; Abdalla, SH; Bain, BJ; (1999) Thrombocytosis with sideroblastic erythropoiesis: a mixed myeloproliferative myelodysplastic syndrome. Leukemia & Lymphoma , 34 (5-6) pp. 615-619.

Gale, RE; (1999) Evaluation of clonality in myeloid stem-cell disorders. SEMIN HEMATOL , 36 (4) 361 - 372.

Gale, RE; Forbes, LV; Pizzey, A; Pouwels, K; Linch, DC; (1999) A leukemia-associated mutation in the G-CSF receptor implies a role for the transmembrane domain in receptor activation. BLOOD , 94 (10) 45A - 45A.

Gander, M; Hartley, JM; Spanswick, VJ; Webley, SD; Hochhauser, D; Hartley, JA; (1999) Measurment of DNA interstrand crosslinking in clinical samples using the single cell gel electrophoresis. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH , 40 p. 3410.

Garcia, SB; Park, HS; Novelli, M; Wright, NA; ', ; (1999) Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. The Journal of Pathology , 187 (1) pp. 61-81.

Gardiner, C; Harrison, P; Chavda, N; Mackie, IJ; Machin, SJ; (1999) Platelet activation responses in vitro to human mast cell activation. BRIT J HAEMATOL , 106 (1) 208 - 215.

Gardiner, C; Harrison, P; Chavda, N; Mackie, IJ; Machin, SJ; (1999) Platelet aggregation in response to in vitro human mast cell activation. THROMB HAEMOSTASIS 461 - 461.

Gardiner, C; Mackie, IJ; Machin, S; Malia, RG; Jones, DW; Winter, M; Taberner, D; ... Greaves, M; + view all (1999) The impact of different DRVVT calculation methods on lupus anticoagulant testing. British Journal of Haematology , 105 p. 7.

Gardiner, C; Mackie, IJ; Machin, SJ; Taberner, D; Leeming, D; Malia, RG; Jones, DW; ... Greaves, M; + view all (1999) Modification of DRVVT calculation methods improves the specificity of lupus anticoagulants. THROMB HAEMOSTASIS 587 - 587.

Gerhard, DS; Xu, Z; Nguyen, L; Li, Y; Mungall, A; Beck, S; Huettner, P; (1999) The generation of a sequence-ready contig encompassing the cervical tumor suppressor gene (TSG) on 6p23. AM J HUM GENET , 65 (4) A127 - A127.

GlynneJones, R; Saunders, MI; Hoskin, P; Phillips, H; (1999) A pilot study of continuous, hyperfractionated, accelerated radiotherapy in rectal adenocarcinoma. Clinical Oncology , 11 pp. 334-339.

Goodchild, K; Hoskin, P; Dische, S; Pigott, K; Powell, M; Saunders, M; (1999) A feasibility study of continuous hyperfractionated accelerated radiotherapy (CHART) and brachytherapy in patients with early oral or oropharyngeal carcinomas. Radiotherapy and Oncology , 50 pp. 29-31.

Goodchild, KA; Hill, SA; Hoskin, PJ; Saunders, MI; Chaplin, DJ; (1999) Low dose nicotinamide and carbogen improve human tumour blood flow. British Journal of Cancer , 80 p. 244.

Gorodetsky, R; Lotan, C; Piggot, K; Pierce, LJ; Polyansky, I; Dische, S; Saunders, MI; ... Vexler, A; + view all (1999) Late effects of dose fractionation on the mechanical properties of breast skin following post-lumpectomy radiotherapy. International Journal of Radiation Oncology Biology Physics , 45 pp. 893-900.

Gray, E; Mackie, I; Greaves, M; (1999) A strategy for improving the quality of lupus anticoagulant testing: Establishment of the 1st British Reference Plasmas Panel for Lupus Anticoagulant. THROMB HAEMOSTASIS 67 - 67.

Green, AJ; Adamson, KL; Begent, RH; (1999) Validation of a gamma camera PET system for serial 18F-FDG imaging for the measurement of response to anti-cancer therapies. Journal of Nuclear Medicine , 40 p. 1246.

Griffin, RJ; Barlow, HC; Curtin, NJ; Calvert, AH; Golding, BT; Newell, DR; Smith, PG; (1999) 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP). Clinical Cancer Research , 5 564-.

Griffioen, A; Sabin, CA; Devereux, H; Yee, TT; Lee, CA; (1999) Natural history of hepatitis C virus in a cohort of individuals with clotting factor disorders treated with unsterilised clotting concentrates. THROMB HAEMOSTASIS 475 - 476.

Griffioen, A; Sabin, CA; Devereux, H; Yee, TT; Lee, CA; (1999) Natural history of hepatitis C virus in a cohort of individuals with clotting factor disorders treated with unsterilised clotting concentrates. BRIT J HAEMATOL , 105 50 - 50.

Grimaldi, KA; Bingham, JP; Hartley, JA; (1999) PCR-Based Assys for Strand-Specific Measurement of DNA Damage and Repair I. In: Henderson, DS, (ed.) Methods in Molecular Biology. (pp. 227-241). Humana Press Inc

Grimaldi, KA; Mac Adam, SR; Hartley, JA; (1999) PCR-Based Assys for Strand-Specific Measurement of DNA Damage and Repair II. In: Henderson, DS, (ed.) Methods in Molecular Biology. (pp. 241-255). Humana Press

Guo, AL; Zhong, S; Ronchetti, S; Ruggero, D; Salomoni, P; Pandolfi, PP; (1999) PML is required for the ability of DAXX to regulate programmed cell death. BLOOD , 94 (10) 489A - 489A.

H

Hackshaw, A; Wald, NJ; Ayme, A; (1999) Statement from panel on antenatal screening for Down syndrome. In: Beazoglou, T and Benn, P and Cuckle, H and Haddow, J and Kyriopoulos, J, (eds.) Down syndrome: Screening policy and economic evaluations. (pp. 261-265). National School of Public Health, Exandus Publishers, Athens

Hamdulay, SS; Wickremasinghe, RG; Prentice, HG; Hoffbrand, AV; Mehta, AB; Ganeshaguru, K; (1999) Differential expression of the alternatively spliced STAT-1 alpha and beta mRNA and its products in B-CLL and tonsillar B-cells. BRIT J HAEMATOL , 105 86 - 86.

Harris, NL; Isaacson, PG; (1999) What are the criteria for distinguishing MALT from non-MALT lymphoma at extranodal sites? American Journal of Clinical Pathology , 111 (1 supp) S126-S132.

Harrison, CN; Gale, RE; Mire-Sluis, A; Machin, SJ; Linch, DC; (1999) Essential thrombocythaemia with polyclonal haemopoiesis is not due to disruption in levels of interleukins-6,-11, thrombopoietin, or transforming growth factor beta 1 levels. BLOOD , 94 (10) 112A - 112A.

Harrison, CN; Gale, RE; Pezella, F; Mire-Sluis, A; Machin, SJ; Linch, DC; (1999) Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. British Journal of Haematology , 107 (1) pp. 139-147. 10.1046/j.1365-2141.1999.01667.x.

Harrison, CN; Gale, RE; Pezella, F; Mire-Sluis, A; Machin, SJ; Linch, DC; (1999) Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. BRIT J HAEMATOL , 107 (1) 139 - 147.

Harrison, CN; Gale, RE; Pezzella, F; Mire-Sluis, A; Machin, SJ; Linch, DC; (1999) Platelet c-mpl expression and plasma thrombopoietin levels are dysregulated in patients with thrombocytosis; regardless of clonal status. British Journal of Haematology , 107 pp. 139-147.

Harrison, P; Robinson, M; Khair, K; Liesner, R; Carr, P; Criddle, S; Mackie, I; (1999) The PFA-100(R) - A potential screening tool for the assessment of platelet dysfunction. THROMB HAEMOSTASIS 743 - 743.

Harrison, P; Robinson, MSC; Mackie, IJ; Joseph, J; McDonald, SJ; Liesner, R; Savidge, GF; ... Machin, SJ; + view all (1999) Performance of the platelet function analyser PFA-100® in testing abnormalities of primary haemostasis. Blood Coagulation and Fibrinolysis , 10 (1) pp. 25-31.

Haynes, AP; Kottiridis, P; Byrne, JL; Goldstone, A; Russell, NH; Linch, DC; McKinnon, S; (1999) Results of allogeneic transplantation for lymphoma - A report on 41 patients. BRIT J HAEMATOL , 105 87 - 87.

Hennesey, BJ; Mehta, AB; Kibbler, C; Hoffbrand, AV; (1999) Case Report: Candida glabrata fungal ball in the oesophagus. CME Bulletin Haematology , 2 pp. 100-101.

Henriquez, NV; Floettmann, E; Salmon, M; Rowe, M; Rickinson, AB; (1999) Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1. pp. 3298-3307.

Heppell-Parton, AC; Nacheva, E; Carter, NP; Bergh, J; Ogilvie, D; Rabbitts, PH; (1999) Elucidation of the mechanism of homozygous deletion of 3p12-13 in the U2020 cell line reveals the unexpected involvement of other chromosomes. Cancer Genet Cytogenet , 111 (2) pp. 105-110.

Heppell-Parton, AC; Nacheva, E; Carter, NP; Rabbitts, PH; (1999) A combined approach of conventional and molecular cytogenetics for detailed karyotypic analysis of the small cell lung carcinoma cell line U2020. Cancer Genet Cytogenet , 108 (2) pp. 110-119.

Hernandez, D; Fisher, EMC; (1999) Mouse autosomal trisomy - two’s company, three’s a crowd. Trends in Genetics , 15 pp. 241-247.

Hernandez, D; Mee, PJ; Martin, JE; Tybulewicz, VLJ; Fisher, EMC; (1999) Transchromosomal mouse embryonic stem cell lines that contain a freely segregating whole or partial human chromosome 21. Human Molecular Genetics , 8 (5) pp. 923-933.

Hillmen, P; Richards, SJ; Baker, AJ; Gale, RE; Rawstron, AC; Crawford, DH; Lalloz, MRA; (1999) Congenital paroxysmal nocturnal haemoglobinuria. BRIT J HAEMATOL , 105 64 - 64.

Holmes, Z; Backos, M; Atoyebi, W; Pickering, W; Regan, L; Cohen, H; (1999) Screening for heritable thrombophilic risk factors in a recurrent miscarriage population. In: THROMB HAEMOSTASIS. (pp. 534 - 535). F K SCHATTAUER VERLAG GMBH

Holmes, ZR; Regan, L; Chilcott, I; Cohen, H; (1999) The C677T MTHFR gene mutation is not predictive of risk for recurrent fetal loss. BRIT J HAEMATOL , 105 (1) 98 - 101.

Hoskin, PJ; Abdelath, O; Phillips, H; Gilligan, S; Saunders, MI; Broderick, P; Baddeley, H; (1999) Inspired and expired gas concentrations in man during carbogen breathing. Radiotherapy and Oncology , 51 pp. 175-177.

Hoskin, PJ; Saunders, MI; Abdellati, O; Broderick, P; (1999) Capnometry and blood gas measurements in man during carbogen breathing. British Journal of Cancer , 80 p. 328.

Hoskin, PJ; Saunders, MI; Dische, S; (1999) Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma - Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer , 86 pp. 1322-1328.

Hoskin, PJ; Saunders, MI; Goodchild, K; Powell, MEB; Taylor, NJ; Baddeley, H; (1999) Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. British Journal of Radiology , 72 pp. 1093-1098.

Hoskin, PJ; Stratford, M; Folkes, L; Phillips, H; Jackson, S; Regan, J; Yarnold, JR; (1999) Bone markers in response to local radiotherapy for bone pain. British Journal of Cancer , 80 p. 28.

Hughes, AN; Rafi, I; Griffin, MJ; Calvert, AH; Newell, DR; Calvete, JA; Johnston, A; ... Boddy, AV; + view all (1999) Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. CLIN CANCER RES , 5 (1) 111 - 118.

Hunalov, A; Robson, L; Perkins, SJ; Begent, RHJ; Chester, KA; (1999) A vector for expression of dimeric and chelating forms of anti-CEA scFvS. British Journal of Cancer , 80 p. 92.

Hunalov, A; Robson, L; Perkins, SJ; Begent, RHJ; Chester, KA; (1999) A vector for expression of dimeric and chelating forms of anti-CEA scFvS. BRIT J CANCER , 80 51 - 51.

I

Ings, SJ; Schey, S; Hancock, B; Watts, MJ; Vandenberghe, E; Goldstone, AH; Elston, T; ... Linch, DC; + view all (1999) Results of a BNLI randomized trial of G-CSF dose after cyclophosphamide 1.5g/m(2) for progenitor cell mobilization. BLOOD , 94 (10) 666A - 666A.

Isaacson, PG; (1999) Gastric MALT lymphoma: from concept to cure. Annals of Oncology , 10 (6) pp. 637-645.

Isaacson, PG; (1999) Gastrointestinal lymphomas of T- and B-cell types. Modern Pathology , 12 (2) pp. 151-158.

Isaacson, PG; (1999) Mucosa associated lymphoid tissue lymphoma. Seminars in Hematology , 36 (2) pp. 139-147.

Isaacson, PG; (1999) T-cell lymphoma: the real thing. Human Pathology , 45 (5) p. 639.

Isaacson, PG; Diss, TC; Wotherspoon, AC; Barbazza, R; Boni, M; Doglioni, C; (1999) Long-term follow-up of gastric MALT lymphoma treated by eradication of H pylori with antibodies. Gastroenterology , 117 (3) pp. 750-751.

J

Jennings, BH; Tyler, DM; Bray, SJ; (1999) Target Specificities of Enhancer of split Basic helix-loop-helix proteins in Drosophila. MCB , 19 pp. 4600-4610.

Joiner, MC; Marples, B; Lambin, P; Short, S; Turesson, I; (1999) Low-dose hypersensitivity: current status and possible mechanisms. International Journal of Radiation Oncology Biology Physics , 49 (2) pp. 379-389.

Jones, DT; Wickremasinghe, RG; Mehta, AB; Prentice, HG; Hoffbrand, AV; Ganeshaguru, K; (1999) The putative role of Fas and caspase 8 in the killing of B-CLL cells by cytotoxic drugs and radiation. BLOOD , 94 (10) 310A - 310A.

Jones, DW; Joseph, JE; Donohoe, S; Mackie, IJ; Gallimore, MJ; Winter, M; (1999) Factor XII antibodies in patients with phospholipid antibodies: Are they predictors of thrombotic risk? THROMB HAEMOSTASIS 66 - 67.

Joseph, JE; Harrison, P; Mackie, IJ; Machin, SJ; (1999) Platelet activation and platelet-leukocyte complexes in the primary antiphospholipid syndrome (PAPS) and systemic lupus erythematosus (SLE). THROMB HAEMOSTASIS 68 - 69.

Joseph, JE; Mackie, IJ; Harrison, P; Machin, SJ; (1999) Increased thrombin generation in patients with the primary antiphospholipid syndrome. BRIT J HAEMATOL , 105 44 - 44.

K

Keshtgar, MRS; Kocjan, G; Lakhani, SR; Ell, PJ; (1999) Imprint cytology in sentinel node biopsy in breast cancer: Is it reliable? In: (pp. S0107-).

Keshtgar, MRS; Kocjan, G; Lakhani, SR; Ell, PJ; (1999) Imprint cytology in sentinel node biopsy in breast cancer: Is it reliable? EUR J NUCL MED , 26 (4) S56 - S56.

Keshtgar, MRS; Kocjan, G; Lakhani, SR; Ell, PJ; (1999) Is imprint cytology reliable in sentinel node biopsy for breast cancer? In: (pp. p. 1115).

Keshtgar, MRS; Kocjan, G; Lakhani, SR; Ell, PJ; (1999) Is imprint cytology reliable in sentinel node biopsy for breast cancer? J NUCL MED , 40 (5) 251P - 252P.

Khwaja, A; Hassan, R; Tatton, EL; Watts, M; Linch, DC; (1999) Inhibition of myeloid cell apoptosis by G-CSF and GM-CSF involves different signal transduction pathways depending on the stage of differentiation. BRIT J HAEMATOL , 105 102 - 102.

Kiani-Alikhan, S; Chester, KA; Ledermann, JA; Beverley, PCL; (1999) Potentiation of the activity of dendritic cells by DNA. In: (pp. p. 93).

Kiani-Alikhan, S; Chester, KA; Ledermann, JA; Beverley, PCL; (1999) Potentiation of the activity of dendritic cells by DNA. BRIT J CANCER , 80 52 - 52.

Koh, MBC; Lowdell, MW; Prentice, HG; (1999) The GvH reaction: The 'cytokine storm' and its effect on lymphocyte alloreactive responses. BRIT J HAEMATOL , 105 60 - 60.

Koh, MBC; Prentice, HG; Corbo, M; Cotter, FE; Morgan, M; Ravell, P; Lowdell, MW; (1999) Establishment of the NOD/SCID mouse as a model for allogeneic GvHD. BLOOD , 94 (10) 330B - 330B.

L

Lader, CS; Scopes, J; Horton, MA; Flanagan, AM; (1999) Human osteoclasts generated with soluble trance - Differences from stromal-cell based culture systems. WILEY-BLACKWELL

Langabeer, SE; Grimwade, D; Walker, H; Burnett, AK; Goldstone, AH; Linch, DC; (1999) EV1-1 expression in acute promyelocytic leukaemia. BRIT J HAEMATOL , 105 74 - 74.

Laplace-Marieze, V; Presneau, N; Sylvain, V; Kwiatkowski, F; Lortholary, A; Hardouin, A; Bignon, YJ; (1999) Systematic sequencing of the BRCA-1 coding region for germ-line mutation detection in 70 French high-risk families. INT J ONCOL , 14 (5) 971 - 977.

Lawrie, AS; Mackie, IJ; Purdy, G; Kitchen, S; Howarth, D; Martin, J; Rigsby, P; ... BCSH fibrinogen working party Med, ; + view all (1999) A comparative study of commercial fibrinogen reference preparations, Clauss and PT-derived fibrinogen assay reagents. THROMB HAEMOSTASIS 605 - 605.

Ledermann, JA; Herd, R; Maraninchi, D; Viens, P; Buclon, M; Chauvin, F; Ferrante, P; ... Rosti, G; + view all (1999) UNSPECIFIED In: (Proceedings) High Dose Chemotherapy in Ovarian Cancer:An Analysis of the Experience of the European Group for Blood and Marrow Transplant (EBMT) over 7 Years. (pp. 360a-).

Ledermann, JA; Maughan, TS; James, RD; Kerr, D; McArdle, C; Seymour, M; Johnston, C; (1999) Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (De Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer. British Journal of Cancer , 80 p. 410.

Ledermann, JA; Maughan, TS; James, RD; Kerr, D; McArdle, C; Seymour, M; Johnston, C; ... MRC Colorectal Cancer Working Party, ; + view all (1999) Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (De Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer. BRIT J CANCER , 80 20 - 20.

Lin, CQ; Parrinello, S; Campisi, J; Desprez, PY; (1999) Regulation of mammary epithelial cell phenotypes by the helix-loop-helix protein, Id-1. ENDOCRINE-RELATED CANCER , 6 (1) 49 - 50.

Linch, DC; Goldstone, AH; (1999) High-dose therapy for Hodgkin's disease. BRIT J HAEMATOL , 107 (4) 685 - 690.

Lindh, M; Hannoun, C; Dhillon, AP; Norkrans, G; Horal, P; (1999) Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J INFECT DIS , 179 (4) 775 - 782.

Lindh, M; Savage, K; Rees, J; Garwood, L; Horal, P; Norkrans, G; Dhillon, AP; (1999) HBeAg immunostaining of liver tissue in various stages of chronic hepatitis B. LIVER , 19 (4) 294 - 298.

Lowdell, MW; Craston, R; Prentice, HG; (1999) Generation of autologous immunity to acute myeloid leukaemia and maintenance of complete remission following alpha interferon treatment. BRIT J HAEMATOL , 105 78 - 78.

Lowdell, MW; Wood, ME; Craston, R; Prentice, HG; (1999) Measurement of autologous immunity to leukaemia can predict maintenance of complete remission at two years. BRIT J HAEMATOL , 105 59 - 59.

M

Majumdar, A; Eardley, K; Howie, AJ; Savage, COS; Wheeler, DC; Richards, NT; Adu, D; (1999) Prevalence, predictors and prognostic significance of non-diabetic renal disease (NDRD) in patients with type II diabetes mellitus (NIDM). KIDNEY INT , 55 (6) 2592 - 2592.

Makris, A; Powles, TJ; Allred, DC; Ashley, SE; Trott, PA; Ormerod, MG; Titley, JC; (1999) Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study. Breast Cancer Research And Treatment , 53 pp. 51-59.

Makris, A; Powles, TJ; Kakolyris, S; Dowsett, M; Ashley, SE; Harris, AL; (1999) Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer , 85 pp. 1996-2000.

Mangham, DC; Isaacson, PG; (1999) A novel immunohistochemical detection system using mirror image complementary antibodies (MICA). Histopathology , 35 (2) pp. 129-133.

Mao, X; Barfoot, R; Hamoudi, RA; Easton, DF; Flanagan, AM; Stratton, MR; (1999) Allelotype of uterine leiomyomas. CANCER GENETICS AND CYTOGENETICS , 114 (2) pp. 89-95. 10.1016/S0165-4608(99)00053-9.

Marsh, SG; (1999) Nomenclature for Factors of the HLA System, update September 1998. WHO Nomenclature Committee for Factors of the HLA System. Hum Immunol , 60 (1) pp. 88-89.

Marsh, SG; (1999) Nomenclature for Factors of the HLA system, update August 1998. WHO Nomenclature Committee for Factors of the HLA System. Hum Immunol , 60 (1) 87-.

Marsh, SG; (1999) Nomenclature for factors of the HLA System, update December 1998. WHO Nomenclature Committee for Factors of the HLA System. Hum Immunol , 60 (3) 271-.

Marsh, SG; (1999) Nomenclature for factors of the HLA System, update November 1998. WHO Nomenclature Committee for Factors of the HLA System. Hum Immunol , 60 (3) pp. 269-270.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update April 1999. WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens , 54 (2) pp. 209-211.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update April 1999. WHO Nomenclature Committee for factors of the HLA system. Hum Immunol , 60 (9) pp. 918-919.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update February 1999. Marsh for the WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens , 54 (1) pp. 108-109.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update February 1999. WHO Nomenclature Committee for Factors of the HLA System. Hum Immunol , 60 (5) 451-.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update January 1999. Marsh for the WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens , 54 (1) pp. 106-107.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update January 1999. WHO Nomenclature Committee for Factors of the HLA System. Hum Immunol , 60 (5) 450-.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update July/August 1999. WHO Nomenclature Committee for Factors of the HLA System. Hum Immunol , 60 (11) 1156-.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update July/August 1999. WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens , 54 (5) pp. 531-532.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update June 1999. WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens , 54 (3) pp. 322-324.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update June 1999. WHO Nomenclature Committee for Factors of the HLA system. Hum Immunol , 60 (10) pp. 1011-1012.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update March 1999. Marsh for the WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens , 54 (1) pp. 110-111.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update March 1999. WHO Nomenclature Committee for factors of the HLA system. Hum Immunol , 60 (7) 627-.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update May 1999. WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens , 54 (2) 212-.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update May 1999. WHO Nomenclature Committee for factors of the HLA system. Hum Immunol , 60 (9) 920-.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update October 1998. WHO Nomenclature Committee for Factors of the HLA System. Hum Immunol , 60 (3) 268-.

Marsh, SG; (1999) Nomenclature for factors of the HLA system, update September 1999. WHO nomenclature committee for factors of the HLA system. Hum Immunol , 60 (12) 1310-.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update April 1999. HUMAN IMMUNOLOGY , 60 (9) pp. 918-919.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update April 1999. EUROPEAN JOURNAL OF IMMUNOGENETICS , 26 (5) pp. 379-380. 10.1046/j.1365-2370.1999.00179.x.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update August 1998. HUMAN IMMUNOLOGY , 60 (1) p. 87.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update December 1998. EUROPEAN JOURNAL OF IMMUNOGENETICS , 26 (2-3) p. 247.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update February 1999. HUMAN IMMUNOLOGY , 60 (5) p. 451.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update February 1999. EUROPEAN JOURNAL OF IMMUNOGENETICS , 26 (4) p. 317. 10.1046/j.1365-2370.1999.00171.x.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update January 1999. HUMAN IMMUNOLOGY , 60 (5) p. 450.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update January 1999. EUROPEAN JOURNAL OF IMMUNOGENETICS , 26 (4) p. 315. 10.1046/j.1365-2370.1999.00170.x.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update July/August 1999. EUROPEAN JOURNAL OF IMMUNOGENETICS , 26 (6) p. 427. 10.1046/j.1365-2370.1999.00195.x.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update June 1999. TISSUE ANTIGENS , 54 (3) pp. 322-324.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update June 1999. EUROPEAN JOURNAL OF IMMUNOGENETICS , 26 (5) pp. 383-384. 10.1046/j.1365-2370.1999.00181.x.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update June 1999 - Compiled by Steven G. E. Marsh for the WHO Nomenclature Committee for Factors of the HLA System. HUMAN IMMUNOLOGY , 60 (10) pp. 1011-1012.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update March 1999. EUROPEAN JOURNAL OF IMMUNOGENETICS , 26 (4) p. 319. 10.1046/j.1365-2370.1999.00172.x.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update May 1999. EUROPEAN JOURNAL OF IMMUNOGENETICS , 26 (5) p. 381. 10.1046/j.1365-2370.1999.00180.x.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update November 1998. EUROPEAN JOURNAL OF IMMUNOGENETICS , 26 (2-3) pp. 245-246.

Marsh, SGE; (1999) Nomenclature for factors of the HLA system, update October 1998. EUROPEAN JOURNAL OF IMMUNOGENETICS , 26 (2-3) p. 243.

Mathews, F; Murphy, M; Wald, N; Hackshaw, A; (1999) Twinning and folic acid use. The Lancet , 353 291-.

Mayer, A; Chester, KA; Flynn, AA; Begent, RH; (1999) Taking engineered anti-CEA antibodies to the clinic. J Immunol Methods , 231 (1-2) pp. 261-273.

McDermott, A; Cohen, SBA; Zuckerman, JN; Madrigal, JA; (1999) Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. Vaccine , 17 pp. 330-339.

McHugh, PJ; Gill, RD; Waters, R; Hartley, JA; (1999) Excision repair of nitrogen mustard-DNA adducts in Saccharomyces cerevisiae. NUCLEIC ACIDS RES , 27 (16) 3259 - 3266. Gold open access

McHugh, PJ; Hartley, JA; (1999) The induction and repair of DNA doublestrand breaks in nitrogen mustard treated Saccharomyces cerevisiae cells. BRIT J CANCER , 80 42 - 42.

McLean, M; Bisits, A; Davis, J; Walters, W; Hackshaw, A; de, VK; Smith, R; (1999) Predicting risk of preterm delivery by second trimester measurement of maternal plasma corticotropin-releasing hormone and alpha-fetoprotein. American Journal of Obstetrics and Gynecology , 181 (1) pp. 207-215.

Mchugh, PJ; Hartley, JA; (1999) The induction and repair of DNA doublestrand breaks in nitrogen mustard treated Saccharomyces cerevisiae cells. British Journal of Cancer , 80 p. 54.

N

Nacheva, EP; Sinclair, PB; Laversha, M; Telford, N; Chang, J; Ried, A; Bench, A; ... Green, AR; + view all (1999) Large deletions at the t(9;22) breakpoint are common and may identify a poor prognostic sub group of patients with chronic myeloid leukemia. BLOOD , 94 (10) 534A - 534A.

Nagral, A; Mehta, AB; Gomes, ATB; Ellis, G; Jackson, BFA; Sabin, CA; McIntyre, N; (1999) Serum soluble transferrin receptor in the diagnosis of iron deficiency in chronic liver disease. CLINICAL AND LABORATORY HAEMATOLOGY , 21 (2) pp. 93-97. 10.1046/j.1365-2257.1999.00202.x.

Napier, MP; Hoare, D; Whelan, JS; (1999) Safe administration of high dose methotrexate in osteosarcoma: Carboxypeptidase G2 for idiosynchratic toxicity. British Journal of Cancer , 80 p. 155.

Napier, NP; Hoare, D; Whelan, JS; (1999) Safe administration of high dose methotrexate in osteosarcoma: carboxypeptidase G2 for idiosyncratic toxicity. In:

Newby, JC; Leonard, P; Fenwick, E; Harland, SJ; (1999) A phase II study of epirubicin, carboplatin and infusional 5-FU in hormone resistant prostate cancer. British Journal of Cancer , 80 p. 158.

Newell, DR; Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, P; Endicott, JA; ... Schultz, R; + view all (1999) Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Clinical Cancer Research , 5 124-.

Newell, DR; Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, P; Endicott, JA; ... Schultz, R; + view all (1999) Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. CLIN CANCER RES , 5 3755S - 3755S.

Ng, T; (1999) Imaging Protein Kinase C Activation in Cells. Science , 283 (5410) pp. 2085-2089. 10.1126/science.283.5410.2085.

Ng, TTC; Collins, IE; Kanner, SB; Humphries, MJ; Amft, N; Wickremasinghe, RG; D'Cruz, D; ... Morrow, WJW; + view all (1999) Integrin signalling defects in T-lymphocytes in systemic lupus erythematosus. LUPUS , 8 (1) 39 - 51.

Nitu, IC; Lee, CA; Dhillon, AP; Mistry, PK; (1999) Management of liver failure in a haemophilic patient co-infected with human immunodeficiency and hepatitis C viruses. CLIN LAB HAEMATOL , 21 (2) 139 - 141.

Noble, KE; Wickremasinghe, RG; DeCornet, C; Panayiotidis, P; Yong, KL; (1999) Monocytes stimulate expression of the Bcl-2 family mamber ,A1, in endothelia cells and confer protection against apoptosis. The Journal of Immunology , 162 (3) pp. 1376-1383.

Novelli, MR; Wasan, H; Rosewell, I; Bee, J; Tomlinson, IP; Wright, NA; Bodmer, WF; (1999) Tumor burden and clonality in multiple intestinal neoplasia mouse/normal mouse aggregation chimeras. Proc Natl Acad Sci U S A , 96 (22) pp. 12553-12558.

Novelli, MR; Wasan, H; Tomlinson, IPM; Rosewell, I; Bee, J; Wright, NA; Bodmer, WF; (1999) Polyp number and clonality in Min mouse aggregation chimaeras. Proceedings of the National Academy of Sciences of the United States of America , 96 (22) pp. 12553-12558.

O

Orchard, KH; Cooper, M; Mehta, A; Potter, M; Wijdenes, J; Borchardt, P; Quadri, S; ... Prentice, HG; + view all (1999) Targeted radiotherapy for patients with multiple myeloma: Results of pre-clinical evaluation of candidate antibodies. Blood , 94 p. 4576.

Osborne, M; GlynneJones, R; Galbraith, S; Burcombe, R; Makris, A; (1999) Squamous cell carcinoma antigen as a marker of epidermoid carcinoma of the anal canal. British Journal of Cancer , 80 p. 117.

Osborne, M; GlynneJones, R; Hoskin, P; Saunders, M; Makris, A; (1999) Continuous hyperfractionated accelerated radiotherapy +/-concurrent infusional 5FU in advanced rectal cancer. British Journal of Cancer , 80 p. 114.

Osbourn, JK; McCafferty, J; Derbyshire, EJ; Waibel, R; Chester, K; Boxer, G; Allen, D; (1999) Isolation of a panel of human anti-CEA single chain Fv from a large phage display library. Tumor Targeting , 4 pp. 150-157.

P

Pang, KF; Ganeshaguru, K; Hart, SM; Wickremasinghe, RG; Prentice, HG; Hoffbrand, AV; Mehta, AB; (1999) Expression of the multidrug resistance protein gene homologues in B-CLL and AML cells. BLOOD , 94 (10) 280A - 280A.

Paniwnyk, Z; Pors, K; TeesdaleSpittle, PH; Potter, GA; Plumb, J; Hartley, JA; Patterson, LH; (1999) Novel inhibitor of topo II is effective against resistant ovarian cancer cells. British Journal of Cancer , 80 p. 69.

Papatheodoridis, GV; Barton, SGRG; Andrew, D; Clewley, G; Davies, S; Dhillon, AP; Dusheiko, G; ... Burroughs, AK; + view all (1999) Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. GUT , 45 (3) 427 - 434.

Parkinsoin, MC; Harland, SJ; (1999) Testis cancer. In: Mundy, AR and Fitzpatrick, JM and Neal, DE and George, NJR, (eds.) Scientific Basis of Urology. (pp. 375-394). Isis Medical Media Ltd: Oxford, UK.

Pedley, RB; Sharma, SK; Boxer, GM; Boden, R; Stribbling, SM; Davies, L; Springer, CJ; (1999) Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res , 59 (16) pp. 3998-4003.

Pedley, RB; Sharma, SK; Boxer, GM; Boden, R; Stribbling, SM; Davies, L; Springer, CJ; (1999) Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. CANCER RES , 59 (16) 3998 - 4003.

Plummer, R; Rees, C; Judson, I; Calvert, H; Highley, M; Trigo, J; Jackman, A; ... Smith, M; + view all (1999) Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks. EUR J CANCER , 35 S285 - S285.

Pollard, Y; Watts, MJ; Grant, D; Chavda, N; Linch, DC; Machin, SJ; (1999) Use of the haemopoietic progenitor cell count of the Sysmex SE-9500 to refine apheresis timing of peripheral blood stem cells. BRIT J HAEMATOL , 106 (2) 538 - 544.

Porakishvili, N; Roshupkina, T; Jewell, AP; Patterson, K; Yong, K; Lydyard, PM; (1999) Circulating CD4+ cells in patients with B-chronic lymphocytic leukaemia (B-CLL) express perforin (PF) and serine esterase (SE). Immunology , 98 (Suppl) 20-.

Powell, MEB; Collingridge, DR; Saunders, MI; Hoskin, PJ; Hill, SA; Chaplin, DJ; (1999) Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiotherapy and Oncology , 50 pp. 167-171.

Presneau, N; Laplace-Marieze, V; Sylvain, V; Lortholary, A; Hardouin, A; Bernard-Gallon, D; Bignon, YJ; (1999) Mutation by deletion-insertion in BRCA-1 gene in three unrelated French breast ovarian cancer families: possible implication of a mobile element. B CANCER , 86 (4) 385 - 390.

R

Rege, KP; Bevan, DH; Chitolie, A; Shannon, MS; (1999) Risk factors and thrombosis after airline flight. THROMB HAEMOSTASIS , 81 (6) 995 - 996.

Roberts, PJ; Mollapour, E; Watts, MJ; Linch, DC; (1999) Primitive myeloid cells express high levels of phospholipase A(2) activity in the absence of leukotriene release: Selective regulation by stem cell factor involving the MAP kinase pathway. BLOOD , 94 (4) 1261 - 1272.

Robertson, J; Gale, RE; Linch, DC; Testa, NG; Chopra, R; (1999) Acquired skewed haemopoiesis in the elderly is independent of telomere shortening-implications for stem cell utilisation. BLOOD , 94 (10) 254A - 254A.

Robertson, JD; Gale, R; Wynn, RF; Robinson, SA; Greaves, MJ; Dougal, M; Linch, DC; ... Chopra, R; + view all (1999) Telomere shortening in peripheral blood neutrophils and T cells with age in healthy individuals. BRIT J HAEMATOL , 105 103 - 103.

Robinson, M; Machin, S; Mackie, I; Harrison, P; (1999) In vivo biotinylation studies: Specificity of labelling of reticulated platelets by thiazole orange and mepacrine. THROMB HAEMOSTASIS 826 - 826.

S

Schreuder, GMT; Hurley, CK; Marsh, SGE; Lau, M; Maiers, M; Noreen, H; Setterholm, M; (1999) The HLA dictionary 1999: a summary of HLA-A, -B, -C, –DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. Tissue Antigens , 54 (4) pp. 409-437. 10.1034/j.1399-0039.1999.540412.x.

Schreuder, GMT; Hurley, CK; Marsh, SGE; Lau, M; Maiers, M; Noreen, H; Setterholm, M; (1999) HLA dictionary 1999: a summary of HLA-A, -B, -Cw, –DRB1/3/4/5 and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. Human Immunology , 60 pp. 1157-1181.

Shamash, J; Lee, SM; Deakin, DP; Scarffe, JH; Morgenstern, GR; Chang, J; Gupta, RK; ... Lister, TA; + view all (1999) High dose chemotherapy (HDCT) with autologous haematopoietic support in recurrent or refractory Hodgkin’s lymphoma (HL). In: (Proceedings) British Cancer Research Meeting, Edinburgh.. (pp. 18-). British Journal of Cancer

Shaw, BE; Potter, MN; Pawson, R; Virchis, AE; Patch, D; Murphy, K; Perry, D; (1999) The use of defibrotide in the management of vascular endothelial complications (VOD/HUS/TTP) of stem cell transplantation. BLOOD , 94 (10) 608A - 608A.

Short, S; (1999) UNSPECIFIED In: (Proceedings) The Royal College of Radiologists Annual Scientific Meeting.

Short, S; (1999) The response of human glioma cells to low dose radiation. International journal of radiation biology , 75 pp. 1341-1348.

Short, S; Mayes, C; Woodcock, M; Joiner, MC; (1999) Low-dose hypersensitivity in the T98G glioblastoma cell line. International journal of radiation biology , 75 pp. 847-855.

Sitas, F; Newton, R; Boshoff, C; (1999) Increasing probability of mother-to-child transmission of HHV-8 with increasing maternal antibody titer for HHV-8. NEW ENGL J MED , 340 (24) 1923 - 1923.

Smith, PG; Barlow, HC; Loughlin, P; Huang, B; Bowman, KJ; Calvert, AH; Curtin, NJ; ... Newell, DR; + view all (1999) Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha(1)-acid glycoprotein. British Journal of Cancer , 80 82-.

Smith, PG; Bewley, J; Gogel, JA; Calvert, AH; Newell, DR; Curtin, NJ; Chen, VJ; (1999) MTA (LY231514) induced intracellular dNTP pool pertubations are alleviated by salvage of pre-formed purines and pyrimidines. British Journal of Cancer , 80 83-.

Spanswick, VJ; Hartley, JM; Ward, TH; Hartley, JA; (1999) Measurement of drug-induced DNA interstrand crosslinking using the single-cell gel electrophoresis (comet) assay. Methods Mol Med , 28 pp. 143-154. 10.1385/1-59259-687-8:143.

Speidel, K; Samady, L; Ledermann, JA; Chain, BM; Coffin, R; Katz, D; (1999) Development of transfected dendritic cells for immunotherapy of ovarian cancer. BRIT J CANCER , 80 21 - 21.

Spencer, DIR; Robson, L; Bhatia, J; Sharma, SK; Michael, NP; Whitelegg, NR; Rees, AR; ... Begent, RHJ; + view all (1999) Identifying immunogenic sites on adept enzymes CPG2 using a SCFV phage library & SELDI (TM)-AMS. In: (pp. p. 94).

Spencer, DIR; Robson, L; Bhatia, J; Sharma, SK; Michael, NP; Whitelegg, NR; Rees, AR; ... Bergent, RHJ; + view all (1999) Identifying immunogenic sites on adept enzymes CPG2 using a SCFV phage library & SELDI (TM)-AMS. BRIT J CANCER , 80 52 - 52.

Stein, H; Diehl, V; Marafioti, T; Jox, A; Wolf, J; Hummel, M; (1999) The nature of Reed-Sternberg cells, lymphocytic and histiocytic cells and their molecular biology in Hodgkin’s disease. In: Mauch, P, (ed.) Hodgkin’s Disease. Lippincott Williams &Wilkins-Philadelphia

Steingruber, HE; Dunham, A; Coffey, AJ; Clegg, SM; Howell, GR; Maslen, GL; Scott, CE; ... Ross, MT; + view all (1999) High-resolution landmark framework for the sequence-ready mapping of Xq23-q26.1. GENOME RES , 9 (8) 751 - 762.

Stephens, R; Horton, R; Humphray, S; Rowen, L; Trowsdale, J; Beck, S; (1999) Gene organisation, sequence variation and isochore structure at the centromeric boundary of the human MHC. J MOL BIOL , 291 (4) 789 - 799.

Strauss, S; McTiernan, A; Whelan, JS; (1999) Recurrence of osteosarcoma after disease-free intervals exceeding 5 years. In:

Summers, Y; Middleton, MR; Calvert, H; Lee, SM; Rustin, R; Newell, DR; Thatcher, N; (1999) Effect of temozolomide (TMZ) on central nervous system relapse in patients with advanced melanoma. In: (Proceedings) 1999 ASCO Annual Meeting/35th Annual Meeting, Atlanta, GA.. (pp. 531a-). Proceedings of the American Society of Clinical Oncology

T

Theocharous, P; Lowdell, MW; Jones, AL; Prentice, HG; (1999) Ultrasensitive immunocytochemical and fluorescent detection and characterisation of circulating and micrometastatic tumour cells in patients with breast cancer. BRIT J HAEMATOL , 105 60 - 60.

Thorpe, KL; Schafer, AJ; Genin, E; Trowsdale, J; Beck, S; (1999) Detection of polymorphism in the RING3 gene by high-throughput fluorescent SSCP analysis (vol 49, pg 256, 1999). IMMUNOGENETICS , 50 (1-2) 113 - 113.

Tonks, S; Marsh, SG; Bunce, M; Bodmer, JG; (1999) Molecular typing for HLA class I using ARMS-PCR: further developments following the 12th International Histocompatibility Workshop. Tissue Antigens , 53 (2) pp. 175-183.

Tsuzuki, S; Towatari, M; Saito, H; Enver, T; (1999) Potentiation of gata-factor activities through interactions with tee promyelocytic leukemia protein (PML) and the t(15;17) generated PML-RAR alpha oncoprotein. BLOOD , 94 (10) 258A-259A.

U

UK, FCG; (1999) A multicentre study of combination of Fludarabine phospate, cytosine arabinoside and granulocyte-colony stimulator factor (FLAG) in relapsed and refractory acute myeloid leukaemia and de novo RAEB-T. Trends in Onco-Hematology , 7 (2) pp. 27-29.

V

Vanhaesebroeck, B; Higashi, K; Raven, C; Welham, M; Anderson, S; Brennan, P; Ward, SG; (1999) Autophosphorylation of p110 delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo. EMBO JOURNAL , 18 (5) pp. 1292-1302. 10.1093/emboj/18.5.1292.

Vanhaesebroeck, B; Higashi, K; Raven, C; Welham, M; Anderson, S; Brennan, P; Ward, SG; (1999) Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo. The EMBO Journal , 18 (5) pp. 1292-1302.

Vig, S; Chitolie, A; Maurice, E; Boa, F; Bevan, DH; Halliday, A; Dormandy, J; (1999) Thromboelastography as a screen for hypercoagulable states predicts failure of peripheral arterial intervention. BLOOD , 94 (10) 114B - 114B.

W

Wald, NJ; Hackshaw, AK; (1999) Development and implementation of Down's syndrome screening. In: Beazoglou, T and Benn, P and Cuckle, H and Haddow, J and Kyriopoulos, J, (eds.) Down syndrome: Screening policy and economic evaluations. (pp. 55-68). National School of Public Health, Exandus Publishers, Athens

Watts, MJ; Ings, SJ; Flynn, M; Dodds, D; MacMillan, A; Goldstone, AH; Linch, DC; (1999) Remobilization of poor stem cell mobilizers is clinically worthwhile. BLOOD , 94 (10) 328A - 328A.

Webley, SD; Francis, R; Begent, RHJ; Hartley, JA; Hochhauser, D; (1999) Measurement of the critical DNA lesions produced by antibody directed enzyme prodrug therapy (ADEPT). BRIT J CANCER , 80 47 - 47.

Wedderburn, LR; Maini, MK; Patel, A; Beverley, PCL; Woo, P; (1999) Molecular fingerprinting reveals non-overlapping T cell oligoclonality between an inflamed site and peripheral blood. INT IMMUNOL , 11 (4) 535 - 543.

Whelan, JS; Goodchild, K; Strauss, S; McTiernan, A; Driver, D; Kilby, AM; Cassoni, AM; (1999) Intensive induction therapy (VIDE) including stem cell collection for Ewing's family of tumours. In:

Wickremasinghe, RG; Ganeshaguru, K; Gordon, M; Parsons, A; Hoffbrand, AV; Prentice, HG; Mehta, AB; (1999) The protein tyrosine kinase inhibitor herbimycin A augments cytotoxic drug-induced apoptosis in B-CLL cells cultured with interleukln-4 or autologous plasma. BRIT J HAEMATOL , 105 86 - 86.

Wickremasinghe, RG; Hoffbrand, AV; (1999) Biochemical and genetic control of apoptosis: Relevance to normal hematopoiesis and hematological malignancies. BLOOD , 93 (11) 3587 - 3600.

Wickremasinghe, RG; Hoffbrand, AV; (1999) Molecular basis of leukaemia and lymphoma. In: Provan, D and Gribben, J, (eds.) Molecular Haematology. (pp. 25-41). Blackwell Science: Oxford.

Wickremasinghe, RG; Jones, DT; Gordon, M; Hoffbrand, AV; Prentice, HG; Mehta, AB; Ganeshaguru, K; (1999) Autologous plasma mediates survival of B-CLL cells via activation of the Akt protein kinase. BLOOD , 94 (10) 280A - 280A.

Wickremasinghe, RG; Jones, DT; Hoffbrand, AV; Prentice, HG; Mehta, AB; Ganeshaguru, K; (1999) Caspase 3 activation in the absence of cytoplasmic cytochrome C elevation during apoptotic death of B-CLL cells. BLOOD , 94 (10) 310A - 310A.

Williams, GH; Stoeber, K; (1999) A novel immunoenhanced Pap test. In: Hospital Healthcare Europe 1999/2000. Campden Publishing Limited: London, UK.

Williamson, LM; Lowe, S; Cohen, H; Love, EM; (1999) The 1997/1998 annual SHOT report (on behalf of the serious hazards of transfusion steering group).

Woll, PJ; Carmichael, J; Chan, S; Howell, A; Ranson, M; Miles, D; Calvert, H; (1999) Phase II study results on safety and efficacy of CAELYX (R) (DOXIL (R)) in combination with paclitaxel in the treatment of metastatic breast cancer. EUR J CANCER , 35 S322 - S322.

Y

Yaguchi, H; Yoshida, M; Ejima, Y; Miyakoshi, J; (1999) Effect of high-density extremely low frequency magnetic field on sister chromatid exchanges in mouse m5S cells. Mutat Res , 440 (2) pp. 189-194.

Yong, K; Fahey, A; Thomas, NSB; Inge, S; Watts, M; Linch, DC; (1999) Transendothelial migration of CD34(+) cells requires growth factor activation and occurs predominantly in G(0)/G(1) phase of the cell cycle. BLOOD , 94 (10) 40A - 40A.

Yong, KL; (1999) Blood and its disorders. In: Westwood, OMR, (ed.) The scientific basis for health care. (pp. 417-432). C.V. Mosby

Yong, KL; Jewell, AP; (1999) Diseases of the Central Nervous System. In: Westwood, OMR, (ed.) The scientific basis for health care. (pp. 525-538). C.V. Mosby

Yong, KL; Jewell, AP; (1999) Diseases of the Gut, Liver and Biliary Tract. In: Westwood, OMR, (ed.) The scientific basis for health care. (pp. 461-478). C.V. Mosby

Yong, KL; Jewell, AP; (1999) Diseases of the endocrine system. In: Westwood, OMR, (ed.) The scientific basis for health care. (pp. 479-492). C.V. Mosby

This list was generated on Sun Jun 17 02:29:24 2018 BST.